Generic erosion will constrain hospital-acquired infections drug market growth through 2019

14 December 2010

The advent of generic versions of nine branded agents will significantly constrain growth in the hospital-acquired infections (HAI) drug market through 2019 in the USA, France, Germany, Italy, Spain, the UK and Japan, according to research and advisory firm Decision Resources.

These nine agents - piperacillin/tazobactam (Pfizer's Zosyn/Tazocin, generics), linezolid (Pfizer's Zyvox), daptomycin (Cubist/Novartis' Cubicin), imipenem/cilastatin (Merck & Co's Primaxin), meropenem (AstraZeneca/Cubist's Merrem), ertapenem (Merck's Invanz), doripenem (Shionogi's Finibax/Ortho-McNeil's Doribax), levofloxacin (Johnson & Johnson's Levaquin, Sanofi-Aventis's Tavanic, Daiichi Sankyo's Cravit) and moxifloxacin (Bayer/Merck's Avelox) - garnered 65% of total market sales in the HAI drug market in 2009. Owing to generic erosion, combined sales of these agents will be reduced to 40% of the overall market in 2019.

Uptake of Vibativ, Teflaro and torezolid will help offset downturn

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK